Overview

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Sound Pharmaceuticals, Incorporated
Treatments:
Ebselen